Welcome to our dedicated page for Kazia Therapeuti news (Ticker: KZIA), a resource for investors and traders seeking the latest updates and insights on Kazia Therapeuti stock.
Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development and clinical-stage biotechnology company based in Sydney, Australia. News about Kazia typically centers on the progress of its investigational cancer therapies, particularly its lead program paxalisib, as well as pipeline additions such as EVT801 and a first-in-class PD-L1 protein degrader program.
Company announcements frequently highlight clinical and translational data for paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway. Recent news has included results from glioblastoma studies, early efficacy and biomarker findings in advanced triple-negative breast cancer and HER2-positive metastatic breast cancer, and mechanistic data showing reductions in circulating tumor cells and clusters, changes in tumor cell phenotypes, and reinvigoration of immune cell function.
Kazia’s news flow also covers regulatory and development strategy updates, such as its intention to request FDA Type C meetings to discuss overall survival data in newly diagnosed glioblastoma and potential regulatory pathways, as well as participation in initiatives like an Australian Medical Research Future Fund project using AI-enabled platforms to guide therapy sequencing in diffuse midline glioma and diffuse intrinsic pontine glioma.
Investors following KZIA news will also find information on capital markets activities, including private placements of equity securities, at-the-market offerings of American Depositary Shares, and Nasdaq listing compliance developments. Updates on the EVT801 VEGFR3 inhibitor program, the NDL2 PD-L1 degrader collaboration with QIMR Berghofer, and participation in major oncology conferences provide additional context on Kazia’s evolving pipeline and scientific positioning.
This news page aggregates these disclosures so readers can track key milestones in Kazia’s clinical programs, regulatory interactions, collaborations, and financing events over time.
Kazia (NASDAQ:KZIA) has secured an agreement with Simcere Pharmaceuticals for the Greater China rights to paxalisib. The deal entails an upfront payment of US$11 million, comprising US$7 million in cash and US$4 million in equity. Additionally, the agreement includes up to US$281 million in milestone payments and mid-teen royalties. This strategic move reduces Kazia's expected financing needs from US$14 million to US$7 million and increases the company's valuation to US$215 million, or US$16.60 per basic ADR.
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) has announced a licensing agreement with Simcere Pharmaceutical Group to develop and commercialize its investigational drug, paxalisib, in Greater China. Kazia will receive an upfront payment of US$11 million, including US$7 million in cash and US$4 million in equity. The deal allows Kazia to retain rights outside Greater China and continue its GBM AGILE study. The licensing deal could yield up to US$281 million in milestone payments and royalties from commercial sales, directly funding further development of paxalisib.
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) has entered into an exclusive worldwide license agreement with Oasmia Pharmaceutical AB for Cantrixil, a clinical-stage drug candidate for ovarian cancer. Oasmia will provide an upfront payment of US$ 4 million, with additional milestone payments of up to US$ 42 million, plus royalties on sales. The deal follows positive Phase I study results for Cantrixil, which targets chemotherapy-resistant cancer cells. Oasmia plans to initiate a Phase II trial in 2022.
The Global Coalition for Adaptive Research has activated Kazia's paxalisib and Kintara's VAL-083 in the GBM AGILE trial, aimed at treating glioblastoma, the most aggressive brain cancer. This adaptive platform trial, which began screening patients in 2019, allows simultaneous evaluation of multiple therapies. Paxalisib targets the PI3K/AKT/mTOR pathway, while VAL-083 addresses MGMT resistance. The trial is set to expand to over 30 U.S. sites, enhancing access to cutting-edge therapies for GBM patients.
Kazia Therapeutics Limited (NASDAQ: KZIA) announced a partnership with the Pacific Pediatric Neuro-Oncology Consortium (PNOC) to initiate a clinical trial, PNOC022, focusing on therapies for diffuse midline gliomas, including DIPG. The trial will evaluate multiple therapies, including Kazia's paxalisib, using an adaptive design to streamline assessment. Commencement is expected in early 2021, pending regulatory approvals. This study builds on promising data from previous research and is fully funded by PNOC, showcasing a collaborative effort to advance treatment options for pediatric brain cancer.
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) announces positive top-line results from its phase I study of Cantrixil in patients with advanced ovarian cancer. The study involved 25 patients across the US and Australia, achieving the primary goal of determining a maximum tolerated dose (MTD) of 5 mg/kg. Among 16 evaluable patients, the overall response rate was 19%, with one complete response and two partial responses. Cantrixil was generally well-tolerated, with gastrointestinal side effects reported. Full data is expected to be published in early 2021.
Kazia's latest interim data analysis from its Phase IIa study of paxalisib in glioblastoma multiforme (GBM) shows promising results. The study reports progression-free survival (PFS) of 8.4 months and overall survival (OS) of 17.5 months. The safety data at the full 60mg dose indicates a favorable profile. Additionally, Kazia increased its valuation to US$184 million or US$14.55 per ADR, reflecting higher success probability for paxalisib. This adjustment follows an October US$18 million capital raise, enhancing investor outlook.
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) shared new data on its drug paxalisib at the Society for Neuro-Oncology (SNO) Annual Meeting. The interim analysis of the phase II glioblastoma study indicated a median progression-free survival (PFS) of 8.4 months and overall survival (OS) of 17.5 months, significantly outperforming the standard treatment, temozolomide (PFS: 5.3 months, OS: 12.7 months). The safety profile at a 60mg dose is also consistent with earlier findings. A separate study on pediatric patients showed promising tolerability and pharmacokinetics.
Kazia Therapeutics (NASDAQ: KZIA) has entered a definitive agreement with the Global Coalition for Adaptive Research (GCAR) to join the GBM AGILE pivotal study for glioblastoma. This collaboration will initiate the operational phase of the study, targeting the recruitment of patients for the paxalisib arm, expected to begin in Q1 CY2021. Kazia will pay an initial fee of US$ 5 million to GCAR, with additional milestone payments throughout the study. The GBM AGILE study aims to provide essential clinical evidence for the regulatory approval of paxalisib in key markets.
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) has partnered with Dana-Farber Cancer Institute to explore the use of its drug paxalisib in treating primary CNS lymphoma. This collaboration includes a phase II clinical trial to recruit up to 25 patients, expected to last two years. Paxalisib, a PI3K inhibitor, is the only one in development capable of crossing the blood-brain barrier, targeting a disease that has limited treatment options. Kazia will provide the study drug and financial support from its recent Share Purchase Plan.